MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

14.47 2.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.39

Максимум

14.62

Ключови измерители
By Trading Economics
Приходи	-23M -14M
Продажби	-22M 72M
Марж на печалбата	-18.944
Служители	624
EBITDA	-23M -6.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+44.16% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-632M 2.2B
Предишно отваряне	12.06
Предишно затваряне	14.47

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.04.2026 г., 23:48 ч. UTC

Значими събития в новините

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19.04.2026 г., 23:36 ч. UTC

Значими събития в новините

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19.04.2026 г., 22:47 ч. UTC

Значими събития в новините

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19.04.2026 г., 23:38 ч. UTC

Значими събития в новините

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19.04.2026 г., 23:12 ч. UTC

Значими събития в новините

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19.04.2026 г., 23:10 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19.04.2026 г., 23:09 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19.04.2026 г., 23:08 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18.04.2026 г., 01:00 ч. UTC

Значими събития в новините

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17.04.2026 г., 22:58 ч. UTC

Печалби

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17.04.2026 г., 21:32 ч. UTC

Пазарно говорене

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Moody's Downgrades Belgium to A1 -- Market Talk

17.04.2026 г., 20:52 ч. UTC

Печалби

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.04.2026 г., 20:29 ч. UTC

Печалби

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

44.16% нагоре

12-месечна прогноза

Среден 20.86 USD 44.16%

Висок 22 USD

Нисък 20 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.